{
  "abstract": "Background and Importance Non-squamous non-small-cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality in Spain. Despite significant therapeutic advances in recent years, the available therapeutic options remain limited. In this context, the antibody–drug conjugate Datopotamab-Deruxtecan (Dato-dx) has emerged as the current standard of care for patients with lung adenocarcinoma.This drug hasn’t been commercialised in Spain yet, so the access to it is made through the application ‘Medicamentos en Situaciones Especiales’ of the Ministry of Health.Aim and Objectives To analyse the effectiveness of Dato-dx versus Docetaxel-nintendanib in patients with metastatic non-squamous-NSCLC.Material and Methods Observational, retrospective, single-centre study that included all patients with metastatic non-squamous-NSCLC who have received prior systemic therapy. Patients were treated with Dato-dx 6 mg/kg or Docetaxel-nintedanib 50 mg/m 2 one every three weeks and were followed-up until August-2024. Sociodemographic, clinical and treatment-related data were collected using the hospital’s electronic medical record program and the Farmis-Oncofarm. The effectiveness variable used was the median of progression-free survival (PFS) and overall survival rate (OS) was estimated using the Kaplan–Meier method.Results A total of 21 patients were included; seven treated with Dato-DXd, with a median age of 65 years (55–76) and 50% of the patients ECOG 1. The median follow-up was 5.3 months (0.1–9.1) and the median number of cycles received was four (1–13). In the Docetaxel-nintedanib arm (n=14), the median age was 62 years (54–80), with 20.43% of the patients ECOG 1. The median follow-up was 2.03 months (0–19,1) and the median number of cycles received was five (1–39).The median PFS was 6 months (95% CI, 2.3-NA) with Dato-DXd and 2.5 months (95% CI, 1.4 to 6.3) with docetaxel ((HR): 1.78 (95% CI 0.63-5.04); P = 0.277). The OS rate at 12 months was 57,1% (95% CI 30,1-100%) and 21.4% (95% CI, 7.9-58,4%) respectively.Conclusion and Relevance Although the difference did not reach statistical significance the data suggest a favourable trend towards Dato-DXd, which could reflect its potential in terms of progression-free survival duration. These results suggest that Dato-DXd could be a promising therapeutic option for previously treated patients with metastatic non-squamous non-small-cell lung cancer.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "E Villarroya Peiró"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "C Herranz Muñoz"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "C Mateos Salillas"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "M Escario Gómez"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "G Casado Abad"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "M Garcia-Trevijano Cabetas"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "L Sánchez-Rubio Ferrández"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "A Soto Rosa"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "ME Ibáñez Ronco"
    },
    {
      "affiliations": [
        "Hospital Universitario La Paz, Pharmacy Department, Madrid, Spain"
      ],
      "name": "A Herrero Ambrosio"
    }
  ],
  "title": "4CPS-157 Effectiveness of datopotamab deruxtecán in metastatic non-squamous non-small-cell lung cancer: real-world experience",
  "uid": "cdd9e94e-0bfd-5c13-a6cb-271f8ab029eb"
}